MedTrace Logo

Safety of "Ticagrelor+ Warfarin"in Comparison With "Clopidogrel+Aspirin+Warfarin"

NCT02206815 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 296

Last updated 2023-04-14

No results posted yet for this study

Summary

The aim of this study was to assess safety of antithrombotic drug ticagrelor plus oral anticoagulation adopted in persistent or permanent AF(Atrial fibrillation) patients（CHA2DS2VASc≥2） after PCI-S with specially regard to the occurrence of major bleeding complications. We hypothesized that baseline characteristics (ie age, anemia, previous major bleeding) and type of antithrombotic regimen could influence any bleeding events and the time of bleeding occurrence. We will test this hypothesis by comparing those AF patients who subsequently received double antithrombotic therapy (Ticagrelor + Warfarin) vs. triple antithrombotic therapy (Clopidogrel + Aspirin + Warfarin) after undergoing PCI-S.

Conditions

Interventions

DRUG

Ticagrelor+Warfarin

Ticagrelor 90mg/bid + Warfarin (maintain INR 2.0-2.5)

DRUG

Clopidogrel+Aspirin+Warfarin

Clopidogrel 75mg/day + Aspirin 100mg/day + Warfarin(maintain INR 2.0-2.5)

Sponsors & Collaborators

  • Zhongda Hospital

    collaborator OTHER

  • Genshan Ma

    lead OTHER

Principal Investigators

  • Genshan Ma, PhD. · Southeast University

  • Yu Wang, MD. · Southeast University

  • Yuyu Yao, Ph.D · Southeast University

  • Wenbin Lu, MD. · Southeast University

  • Cong Fu, MD. · Southeast University

  • LIjuan Chen, PhD. · Southeast University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-19
Primary Completion
2019-02-20
Completion
2019-02-20

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02206815 on ClinicalTrials.gov